May 7, 2021 Joseph Keller

Health Crisis Leads to Surge in Medical Technology Innovation

Medical Technology Innovation

A combination of medical applications for digital internet-of-things technologies coming into their own, and an explosion of interest in the healthcare sector spurred on by the global health crisis is sending the healthcare technology space into a period of incredible innovation. Healthcare technology companies like Mednow Inc. (TSXV:MNOW), Hologic, Inc (NASDAQ:HOLX), Microsoft Corporation (NASDAQ:MSFT), Medtronic plc (NYSE:MDT), and Amwell (NYSE:AMWL) are developing new systems and devices to improve the accessibility of health services, monitor at-risk patients, more easily and accurately diagnose patients, and much more.

Mednow Expands Suite of Healthcare Technologies Throughout Canada

Few segments of the healthcare technology space have more momentum right now than telehealth. One of the dominant North American telehealth companies is Mednow Inc. , a Canadian company with a holistic suite of healthcare technologies, including sophisticated e-pharmacy and telehealth services currently expanding throughout the Canadian market.

Mednow’s suite of healthcare technologies includes both hardware as well as software. Among the company’s offerings is Karie, an at-home device that automatically organizes and dispenses medications as needed based on the user patient’s schedule. The device uses specialized medication pouches that are delivered by Mednow’s e-pharmacy. Karie’s user-friendly interface teaches patients and family members how to use the system and makes the process of managing prescriptions safe and easy.

On March 19, 2020, Mednow announced a significant step forward in its rapid national expansion and development plans: the company has submitted an application for a pharmacy license for a Winnipeg-based fulfillment center. Subject to receiving approval for the application, Mednow is aiming to be operational in Manitoba by this year’s third quarter. The announcement reflects an important milestone in the company’s plans to be a nation-wide service, and was continued upon by its recent announcement that it had also filed an application for a pharmacy license with the Nova Scotia College of Pharmacists. The company has secured a lease for a fulfillment center in Nova Scotia, which is also expected to become operational by Q3 2021.

“We are rapidly advancing our national expansion strategy. Through our fulfillment centers in Ontario and British Columbia, we can service those two entire provinces and with same-day delivery in the Greater Vancouver and Greater Toronto areas,” Mednow CEO Karim Nassar said in the company’s release. “National coverage is imperative to our long-term success and our goal of becoming a household name in Canadian healthcare. Furthermore, a national presence will open the business-to-business market whereby Mednow will be able to partner with employers and employee benefits providers to provide holistic healthcare solutions.” At the same time Mednow is setting up the Manitoba fulfillment center, the company will also be working on deploying centers in two additional provinces.

A Surge in Healthcare Tech Development

On April 14, Microsoft Corporation (NASDAQ:MSFT) announced that it had partnered with French multinational insurance company AXA to build a new digital healthcare platform that will utilize Microsoft’s cloud-based computing and artificial intelligence expertise along with AXA’s experience in the healthcare space. The two companies say that the platform will include a range of healthcare tools including a self-assessment and prevention tool, a medical concierge, a teleconsultation interface, a digital document vault, medication delivery, and an extensive global network of healthcare professionals.

Medical technology company Medtronic plc (NYSE:MDT) announced on April 27 that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration for an experimental catheter device that uses a microwave generator and a digital lung navigation platform to provide localized, minimally invasive treatment of malignant lesions in the lung. Breakthrough Device Designation allows for priority review of medical devices that could have a significant impact on serious treatment needs. The technology, called the Emprint ablation catheter kit, could potentially allow for less invasive treatment and management of malignant lung lesions without the need for surgery or radiotherapy.

Hologic, Inc (NASDAQ:HOLX) has been developing molecular diagnostics technology in response to the global health crisis in partnership with Thermo Fisher. The two companies’ CEOs said during recent investor calls that vaccine rollouts could impact demand for the product, but that the market for this type of diagnostic technology will remain strong long after the health crisis.

In late April, telehealth company Amwell (NYSE:AMWL) announced Converge, the company’s most recent virtual care platform. The platform facilities connectivity for third-party medical devices such as internet-of-things connected vital trackers. The system uses flexible and scalable open architecture to enable collaboration in a wide ecosystem of interconnected medical devices.

One positive legacy of this global health crisis might be the explosion of innovation and development in the healthcare technology sector that we have seen. Technologies developed and marketed by companies like Mednow could provide value for years to come.

Click here to find out more about Mednow Inc. (TSXV:MNOW).

Featured image: DepositPhotos ©️ simpson33

 

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT.  This communication is a paid advertisement for Mednow Inc. (“Mednow” or the “Company”) to enhance public awareness of the Company, its products, its industry and as a potential investment opportunity.  NativeAds, Inc. (“NativeAds”) and its owners, managers, employees, and assigns were paid by the Company to create, produce and distribute this advertisement, as previously disclosed in the news release of the Company dated March 12, 2021.  This compensation should be viewed as a major conflict with NativeAds’ ability to be unbiased. 

This communication is not intended as, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Company purport to provide a complete analysis of the Company or its financial position. The Company is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

This communication is based on information generally available to the public and on and does not contain any material, non-public information.

FORWARD-LOOKING STATEMENTS.  This communication includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the timing of operations beginning in Manitoba, Saskatchewan and Nova Scotia, receipt of all required regulatory approvals from the Manitoba College of Pharmacists, the Nova Scotia College of Pharmacists and other regulatory bodies with oversight of pharmacy practices, the ability to service clients in Saskatchewan and Manitoba from the Manitoba fulfillment centre, the ability to service clients in Nova Scotia from the Nova Scotia fulfillment centre and the benefits of a national presence. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends,” “anticipates,” “it is expected,” or variations of such words and phrases, or statements that certain actions, events or results “may,” “could,” “should,” or “would” occur. Forward-looking statements are based on certain material assumptions and analyses made by management of the Company and the opinions and estimates of management of the Company as of the date of this communication, including that the transactions contemplated herein will close on the terms and timeline as anticipated by the management of the Company and that the Company will receive all required regulatory approvals. Although the Company considers these assumptions to be reasonable based on information currently available to them, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, the risk that the transactions contemplated herein will not close on the terms and timeline as anticipated by the management of the Company, or at all, the risk that the Company will not receive required regulatory approvals and the other risks and uncertainties applicable to the Company and the business of the Company as set forth in the Company’s final long form prospectus dated February 26, 2021 and its other disclosure available under the Company’s profile at www.sedar.com. There can be no assurance that the transactions contemplated in this communication will complete. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations. We seek safe harbor.

 RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

Please See Disclaimer

If You Liked This Article Click To Share

STOCKS YOU MAY LIKE


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Mednow.ca. Market Jar Media Inc. has or expects to receive from Mednow.ca’s Digital Marketing Agency of Record (Native Ads Inc.) three hundred seventy nine thousand CAD for 52 days (37 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on MicroSmallCap.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on MicroSmallCap.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.
MEDNOW DISCLAIMER

Forward Looking Information

This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mednow’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mednow’s industry; (b) market opportunity; (c) Mednow’s business plans and strategies; (d) services that Mednow intends to offer; (e) Mednow’s milestone projections and targets; (f) Mednow’s expectations regarding receipt of approval for regulatory applications; (g) Mednow’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mednow’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mednow’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mednow’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mednow’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mednow’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mednow to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mednow’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Mednow’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mednow’s business operations (e) Mednow may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Mednow undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mednow nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mednow nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

Historical Information

Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mednow or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mednow or such entities and are not necessarily indicative of future performance of Mednow or such entities.